Literature DB >> 22350488

Recent successes of cancer immunotherapy: a new dimension in personalized medicine?

Christophe Caux, Laurence Zitvogel.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22350488     DOI： 10.1007/s11523-012-0211-3

Source DB:  PubMed          Journal:  Target Oncol        ISSN： 1776-2596            Impact factor:   4.493


× No keyword cloud information.
  15 in total

Review 1.  Immunological aspects of cancer chemotherapy.

Authors:  Laurence Zitvogel; Lionel Apetoh; François Ghiringhelli; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2008-01       Impact factor: 53.106

Review 2.  Cancer immunotherapy--revisited.

Authors:  W Joost Lesterhuis; John B A G Haanen; Cornelis J A Punt
Journal:  Nat Rev Drug Discov       Date:  2011-08-01       Impact factor: 84.694

Review 3.  Immunosuppressive networks in the tumour environment and their therapeutic relevance.

Authors:  Weiping Zou
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

Review 4.  Immune parameters affecting the efficacy of chemotherapeutic regimens.

Authors:  Laurence Zitvogel; Oliver Kepp; Guido Kroemer
Journal:  Nat Rev Clin Oncol       Date:  2011-03       Impact factor: 66.675

Review 5.  Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know.

Authors:  Steven A Rosenberg
Journal:  Nat Rev Clin Oncol       Date:  2011-08-02       Impact factor: 66.675

Review 6.  Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy.

Authors:  Mario P Colombo; Silvia Piconese
Journal:  Nat Rev Cancer       Date:  2007-11       Impact factor: 60.716

Review 7.  Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines.

Authors:  Cornelis J M Melief; Sjoerd H van der Burg
Journal:  Nat Rev Cancer       Date:  2008-05       Impact factor: 60.716

Review 8.  Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses.

Authors:  Shimon Sakaguchi
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

9.  Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.

Authors:  Philip W Kantoff; Thomas J Schuetz; Brent A Blumenstein; L Michael Glode; David L Bilhartz; Michael Wyand; Kelledy Manson; Dennis L Panicali; Reiner Laus; Jeffrey Schlom; William L Dahut; Philip M Arlen; James L Gulley; Wayne R Godfrey
Journal:  J Clin Oncol       Date:  2010-01-25       Impact factor: 44.544

Review 10.  Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival.

Authors:  Michel Morre; Stéphanie Beq
Journal:  Target Oncol       Date:  2012-03-02       Impact factor: 4.493
View more
  2 in total

1.  Molecular mimics of the tumour antigen MUC1.

Authors:  Tharappel C James; Ursula Bond
Journal:  PLoS One       Date:  2012-11-14       Impact factor: 3.240

2.  Improving lung cancer survival; time to move on.

Authors:  Marlies E Heuvers; Joost P Hegmans; Bruno H Stricker; Joachim G Aerts
Journal:  BMC Pulm Med       Date:  2012-12-13       Impact factor: 3.317
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.